Advertisement

Clinical Rheumatology

, Volume 29, Issue 4, pp 381–388 | Cite as

Incidence of cancer among female patients with systemic lupus erythematosus in Korea

  • Kwi Young Kang
  • Hyun Ok Kim
  • Ho Sung Yoon
  • Jeniffer Lee
  • Won Chul Lee
  • Hyek-Jae Ko
  • Ji Hyeon Ju
  • Chul-Soo Cho
  • Ho-Youn Kim
  • Sung-Hwan Park
Original Article

Abstract

This study aims to ascertain the incidence of cancer in patients with systemic lupus erythematosus (SLE) in comparison with that in the general population in Korea, and to identify the cancer-types, the organ involvement, and the association with immunosuppressive therapy. The study subjects were consecutive SLE patients evaluated at Kangnam St. Mary’s hospital between 1997 and 2007. The incidence rate of cancer was calculated and was analyzed in comparison to that of age- and sex-matched cohort obtained from the Korea National Cancer Registry. Nine hundred fourteen patients were observed for a total of 5,716 person-years. A total of 16 cases of cancer occurred. The average age at the diagnosis of cancer and the mean disease duration were 43 years and 11 years, respectively. The standardized incidence ratio (SIR) of all cancers was 1.45 (95% CI 0.74–2.16); The SIRs for the three most frequent cancers were 3.42 for cervix cancer (CI 0.00–7.26), 15.37 for non-Hodgkin’s lymphoma (NHL; CI 2.90–37.68), and 43.55 for bladder cancer (CI 8.21–106.78). There were significant differences in the hematologic and renal involvement between SLE patients with cancer and without. Cyclophosphamide therapy, especially with cumulative dose more than 6 g (p = 0.017), seemed to contribute to the increased risk of cancer. Long disease duration, damage, and hematologic involvement were associated with increased risk of cancer occurrence. SLE patients are at high risk for NHL and bladder cancer. Active cancer screening is required in SLE patients with long disease duration and damage who are treated with high dose cyclophosphamide.

Keywords

Bladder cancer Cancer Cyclophosphamide Non-Hodgkin’s lymphoma (NHL) Standardized incidence ratio (SIR) Systemic lupus erythematosus 

Notes

Acknowledgment

Thanks to Hyeon-Woo Yim (Department of Preventive Medicine, The Catholic University of Korea) and Seung Hee Jeong (CMC Clinical Research Coordinating Center, Department of Preventive Medicine, The Catholic University of Korea) for excellent analysis of this data.

This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea Government (MEST; No. R11-2002-098-05003-0)

Disclosures

None.

References

  1. 1.
    Merrel M, Shulman LE (1995) Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis 1:12–32CrossRefGoogle Scholar
  2. 2.
    Pistiner M, Wallace DJ, Nessim S et al (1991) Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21:55–64CrossRefPubMedGoogle Scholar
  3. 3.
    Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestation in a cohort of 1,000 patients. Medicine 82:299–308CrossRefPubMedGoogle Scholar
  4. 4.
    Gripenberg M, Helve T (1991) Outcome of systemic lupus erythematosus. A study of 66 patients over 7 years with reference to the predictive value of anti n-DNA antibody determination. Scand J Rheumatol 20:104–109CrossRefPubMedGoogle Scholar
  5. 5.
    Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, Atzeni F, Piccoli A, Todesco S (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119:700–706CrossRefPubMedGoogle Scholar
  6. 6.
    Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550–2557CrossRefPubMedGoogle Scholar
  7. 7.
    Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA (2002) Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 61:409–413CrossRefPubMedGoogle Scholar
  8. 8.
    Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St Pierre Y, Ramsey-Goldman R, Clarke A (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52:1481–1490CrossRefPubMedGoogle Scholar
  9. 9.
    Parikh-Patel A, White RH, Allen M, Cress R (2008) Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 19:887–894CrossRefPubMedGoogle Scholar
  10. 10.
    Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus 10:394–400CrossRefPubMedGoogle Scholar
  11. 11.
    Bjornadal L, Lofstrom B, Yin L, Lundberg I, Ekbom A (2002) Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31:66–71CrossRefPubMedGoogle Scholar
  12. 12.
    Pettersson T, Pukkala E, Teppo L, Friman C (1992) Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51:437–439CrossRefPubMedGoogle Scholar
  13. 13.
    Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheum 39:1050–1054CrossRefPubMedGoogle Scholar
  14. 14.
    Sultan SM, Ioannou Y, Isenberg DA (2000) Is there an association of malignancy with SLE? An analysis of 276 patients under long-term review. Rheumatology 39:1147–1152CrossRefPubMedGoogle Scholar
  15. 15.
    Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H (2001) Malignancies during follow-up in an epidemiologically defined SLE inception cohort in southern Sweden. Lupus 10:500–504CrossRefPubMedGoogle Scholar
  16. 16.
    Chun BC, Bae SC (2005) Mortality and cancer incidence in Korean patients with systemic lupus erythematosus: results from the Hanyang lupus cohort in Seoul, Korea. Lupus 14:635–638CrossRefPubMedGoogle Scholar
  17. 17.
    Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Szegedi G, Kiss E (2007) Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center. Ann N Y Acad Sci 1108:76–82CrossRefPubMedGoogle Scholar
  18. 18.
    Ragnarsson O, Gröndal G, Steinsson K (2003) Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 12:687–691CrossRefPubMedGoogle Scholar
  19. 19.
    Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMedGoogle Scholar
  20. 20.
    Isenberg DA, Gladman DD (2001) The systemic lupus international collaborating clinics group: origins and outcomes. Lupus 10:375–377CrossRefPubMedGoogle Scholar
  21. 21.
    Incidence in Korea 1999–2001 (2005) Ministry of Health and Welfare, Republic of KoreaGoogle Scholar
  22. 22.
    Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin P, Gordon C, Barr S, Edworthy S, Bae SC, Petri M, Sibley J, Isenberg D, Rahman A, Steinsson K, Aranow C, Dooley MA, Alarcon GS, Hanly J, Sturfelt G, Nived O, Pope J, Ensworth S, Rajan R, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R (2005) Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 53:781–784CrossRefPubMedGoogle Scholar
  23. 23.
    Mellemkjer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with SLE. Arthritis Rheum 40:761–768CrossRefGoogle Scholar
  24. 24.
    Hansen A, Lipsky PE, Dörner T (2007) B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol 3:561–569CrossRefPubMedGoogle Scholar
  25. 25.
    Youinou P et al (2006) B lymphocytes in the front line of autoimmunity. Autoimmun Rev 5:215–221CrossRefPubMedGoogle Scholar
  26. 26.
    Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764–766CrossRefPubMedGoogle Scholar
  27. 27.
    Dörner T, Lipsky PE (2002) Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren’s syndrome. Arthritis Res 4:360–371CrossRefPubMedGoogle Scholar
  28. 28.
    Abu-Shakra M, Ehrenfeld M, Shoenfeld Y (2002) Systemic lupus erythematosus and cancer: associated or not? Lupus 11:137–144CrossRefPubMedGoogle Scholar
  29. 29.
    Bernatsky S, Joseph L, Boivin JF, Gordon C, Urowitz M, Gladman D, Fortin PR, Ginzler E, Bae SC, Barr S, Edworthy S, Isenberg D, Rahman A, Petri M, Alarcón GS, Aranow C, Dooley MA, Rajan R, Sénécal JL, Zummer M, Manzi S, Ramsey-Goldman R, Clarke AE (2008) The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 67:74–79CrossRefPubMedGoogle Scholar
  30. 30.
    Chow SK, Looi LM, Loh CS, Yeap SS (2002) Cyclophosphamide-induced transitional cell carcinoma of bladder in lupus nephritis. Intern Med J 32:114–116CrossRefPubMedGoogle Scholar
  31. 31.
    Ortiz A, Gonzalez-Parra E, Alvarez-Costa G, Egido J (1992) Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron 60:378–379CrossRefPubMedGoogle Scholar
  32. 32.
    Thrasher JB, Miller GJ, Wettlaufer JN (1990) Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J Urol 143:119–121PubMedGoogle Scholar
  33. 33.
    Canoso JJ, Cohen AS (1974) Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis Rheum 17:383–390CrossRefPubMedGoogle Scholar
  34. 34.
    Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, McCune WJ (2004) Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 31:1763–1767PubMedGoogle Scholar
  35. 35.
    Lopez Dupla M, Khamashta M, Pintado Garcia V, Lavilla Uriol P, Valencia Ortega E, Gil Aguado A (1993) Malignancy in systemic lupus erythematosus: a report of five cases in a series of 96 patients. Lupus 2:377–380CrossRefPubMedGoogle Scholar
  36. 36.
    McCune WJ, Riskalla M (2002) Immunosuppressive drug therapy. In: Wace DJ, Hahn B (eds) Dubois’ lupus erythematosus, 6th edn. Linppincott Williams & Wilkins, Philadelphia, pp 1195–1217Google Scholar
  37. 37.
    Asten P, Barrett J, Symmons D (1999) Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26:1705–1714PubMedGoogle Scholar
  38. 38.
    Wells CK, Peduzzi PN, Feinstein AR (2001) Presenting manifestations, cigarette smoking, and detection bias in age at diagnosis of lung cancer. Ann Epidemiol 11:239–247CrossRefPubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2009

Authors and Affiliations

  • Kwi Young Kang
    • 1
  • Hyun Ok Kim
    • 1
  • Ho Sung Yoon
    • 1
  • Jeniffer Lee
    • 1
  • Won Chul Lee
    • 2
  • Hyek-Jae Ko
    • 1
  • Ji Hyeon Ju
    • 1
  • Chul-Soo Cho
    • 1
  • Ho-Youn Kim
    • 1
  • Sung-Hwan Park
    • 1
  1. 1.Division of Rheumatology, Department of Internal MedicineThe Catholic University of KoreaSeoulSouth Korea
  2. 2.Department of Preventive Medicine, College of MedicineThe Catholic University of KoreaSeoulSouth Korea

Personalised recommendations